Aesica Announces Partnership with Bradford University
News Jan 14, 2013
Aesica has announced a partnership with the Centre for Pharmaceutical Engineering Science at the University of Bradford, which will enable the team at Bradford to utilize the GMP capabilities and assets held at Aesica, while Aesica will benefit from the Centre’s extensive research facilities.
The partnership was formed following a presentation from Dr. Riddhi Shukla, business development manager at the Centre for Pharmaceutical Engineering Science to the Aesica Innovation Board and builds upon the relationship established in 2009 between both parties.
The Centre offers a number of processing technologies including hot melt extrusion, but relies on the GMP expertise of the formulation development team at Aesica to manufacture GMP clinical trial supplies.
Speaking of the partnership, Paul Titley, managing director, Formulation Development, Aesica says: “We provide GMP contract manufacturing services to six other universities, but this partnership is particularly important and unique as it is mutually beneficial. While the team at Bradford has development expertise in several key approaches and as such can evaluate the viability of compounds presented by virtual and small pharma organizations, our GMP expertise is crucial to take the compounds into clinical trials, which is vital. By working with such organizations at an early stage we would hope to cement long term development and manufacturing partnerships and expedite the leap from concept to commercialization with a clear and proven route to market. In addition, the facilities at the Centre for Pharmaceutical Engineering Science will enable us to further enhance our overall formulation development service offering which will add value to our existing clients.”
Dr. Shukla adds: “Aesica is a well established pharmaceutical company with exemplary GMP credentials, which we were keen to tap into for the benefit of our contacts within the multinational pharma community. Our facilities at the Centre are second to none and we believe this coupled with our research expertise will deliver significant benefits to Aesica as the partnership evolves.”
The partnership follows a sustained period of expansion by Aesica, which has seen the CMO double its workforce and establish three manufacturing sites in Europe and drive forward plans to expand its offer across America.
In addition, Aesica has recently announced plans to create up to 100 new jobs at its Queenborough, UK, facility between now and 2015 as the site prepares for significant expansion.
Furthermore, the company was recently ranked in The Sunday Times HSBC International Track 200, a newly created list that ranks Britain’s private companies with the fastest growing international sales.
Published in July, the table listed Aesica as the second best performing company in the North East of England after its international sales grew by 37 per cent over the course of the two years to December 2011 - international sales now represent 98 per cent of the company’s overall turnover.
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018